What is the large-scale synthesis process for Pfizer's abrocitinib?
The synthesis of abrocitinib, a Janus kinase 1 (JAK1) inhibitor developed by Pfizer, involves a multi-step process. Key stages include the preparation of a substituted pyrazole core and the subsequent coupling with other molecular fragments. For instance, one reported route involves the preparation of 1-(4-cyanophenyl)-3-methyl-1H-pyrazole-4-carboxylic acid, which serves as a crucial intermediate. This intermediate is then further elaborated through reactions such as amide formation and cyclization to yield the final active pharmaceutical ingredient [1]. The process emphasizes efficiency and scalability for industrial production.
How does abrocitinib's synthesis address large-scale manufacturing challenges?
Large-scale synthesis of abrocitinib requires careful consideration of factors like reagent cost, reaction yield, purification methods, and environmental impact. Process chemistry teams aim to optimize each step to minimize waste and maximize throughput. This often involves selecting commercially viable starting materials and developing robust reaction conditions that are reproducible on a manufacturing scale. The choice of catalysts and solvents also plays a significant role in achieving an economically feasible and environmentally responsible process [1].
What are the key chemical intermediates in abrocitinib's production?
A significant intermediate in the synthesis of abrocitinib is 1-(4-cyanophenyl)-3-methyl-1H-pyrazole-4-carboxylic acid [1]. The efficient and high-purity preparation of this core structure is critical for the subsequent steps. Other intermediates would arise from the coupling and functionalization reactions required to build the complete abrocitinib molecule, including the piperidine ring and the attachment of the sulfonamide moiety.
When do patents for abrocitinib expire?
Information regarding the specific expiration dates of Pfizer's patents for abrocitinib, including process patents, can be found on DrugPatentWatch.com. Patent expiration dictates when generic manufacturers may enter the market [2].
How does abrocitinib compare to other JAK inhibitors?
Abrocitinib is a selective JAK1 inhibitor. Other JAK inhibitors target different combinations of JAK family members (JAK1, JAK2, JAK3, and TYK2). This selectivity can influence their efficacy and safety profiles. For example, some JAK inhibitors may have broader activity across multiple JAK enzymes, potentially leading to different side effect profiles compared to more selective agents like abrocitinib [3].
What is the clinical use of abrocitinib?
Abrocitinib is approved for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents whose disease is not adequately controlled with other medications [3]. It works by inhibiting JAK1, which plays a role in the inflammatory pathways associated with atopic dermatitis.
What are the potential side effects of abrocitinib?
Common side effects associated with abrocitinib include upper respiratory tract infections, nausea, headache, and acne [3]. As with other JAK inhibitors, there are also potential risks such as serious infections, cardiovascular events, thrombosis, and certain malignancies, which are typically outlined in the drug's prescribing information [3].
What is the regulatory status of abrocitinib?
Abrocitinib has received marketing authorization in various regions, including the United States and the European Union, for its approved indication in atopic dermatitis [3]. Regulatory bodies assess the drug's safety and efficacy based on extensive clinical trial data before granting approval.
Who manufactures abrocitinib?
Abrocitinib is developed and manufactured by Pfizer Inc. [3].
---
Cited Sources:
1. DrugPatentWatch.com (General reference for patent information)
2. DrugPatentWatch.com (Specific reference for patent expiration)
3. DrugPatentWatch.com (Information on abrocitinib's mechanism, comparison, clinical use, side effects, and manufacturer)